Late recurrence of melanoma after 10 years - Is the course of the disease different from early recurrences?
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
07
2019
accepted:
17
10
2019
pubmed:
24
11
2019
medline:
15
5
2021
entrez:
24
11
2019
Statut:
ppublish
Résumé
It is known that melanoma can metastasize and recur many years after the first diagnosis. Although predictive and prognostic factors for melanoma are well defined, there is still insufficient information about the factors affecting the recurrence period and the effect of the recurrence time to survival. This study investigates the course of melanoma to show prognostic factors comparing early and late recurrence patients. The main objective is to uncover the effect of the recurrence time on the progression of the disease. In this retrospective study, late recurrence (LR) was defined as melanoma recurrence 10 years after the first diagnosis and early recurrence (ER) was defined as recurrence within 10 years. Gender, age, localization of primary tumour, time to first metastasis, survival rates, histological subtype, stage, tumour thickness, invasion level, ulceration and regression of the primary melanoma were documented. Survival curves were evaluated using the Kaplan-Meier and compared with the log-rank test. Multivariate Cox proportional hazard models were used to identify significant independent prognostic factors for melanoma-specific survival (MSS). A total of 1537 melanoma patients were analysed. Early metastasis was developed in 1438 patients (93.6%), and 99 patients (6.4%) developed late metastasis. Late recurrence patients were younger (P < 0.001) and had fewer ulcerated (P = 0.005), fewer head/neck localized (P = 0.009) and thinner (P < 0.001) melanomas than ER patients. The MSS time (mean ± SD) was nearly identical for LR (31 ± 4.4 months 95% CI [22.3-39.7]) and ER (32 ± 1.9 months [28.3-35.7]). Multivariate regression analysis revealed male gender (hazard ratio [HR = 1.4, P < 0.001), truncal tumour localization (HR = 1.7, P < 0.001), tumour thickness (HR = 1.4, P < 0.045) and ulceration (HR = 1.3, P < 0.008) as significant independent prognostic factors for MSS. Although ER and LR patients are found to have different clinicopathologic features, the time of the first recurrence after diagnosis do not seem to have an effect on the survival.
Sections du résumé
BACKGROUND
BACKGROUND
It is known that melanoma can metastasize and recur many years after the first diagnosis. Although predictive and prognostic factors for melanoma are well defined, there is still insufficient information about the factors affecting the recurrence period and the effect of the recurrence time to survival.
OBJECTIVES
OBJECTIVE
This study investigates the course of melanoma to show prognostic factors comparing early and late recurrence patients. The main objective is to uncover the effect of the recurrence time on the progression of the disease.
METHODS
METHODS
In this retrospective study, late recurrence (LR) was defined as melanoma recurrence 10 years after the first diagnosis and early recurrence (ER) was defined as recurrence within 10 years. Gender, age, localization of primary tumour, time to first metastasis, survival rates, histological subtype, stage, tumour thickness, invasion level, ulceration and regression of the primary melanoma were documented. Survival curves were evaluated using the Kaplan-Meier and compared with the log-rank test. Multivariate Cox proportional hazard models were used to identify significant independent prognostic factors for melanoma-specific survival (MSS).
RESULTS
RESULTS
A total of 1537 melanoma patients were analysed. Early metastasis was developed in 1438 patients (93.6%), and 99 patients (6.4%) developed late metastasis. Late recurrence patients were younger (P < 0.001) and had fewer ulcerated (P = 0.005), fewer head/neck localized (P = 0.009) and thinner (P < 0.001) melanomas than ER patients. The MSS time (mean ± SD) was nearly identical for LR (31 ± 4.4 months 95% CI [22.3-39.7]) and ER (32 ± 1.9 months [28.3-35.7]). Multivariate regression analysis revealed male gender (hazard ratio [HR = 1.4, P < 0.001), truncal tumour localization (HR = 1.7, P < 0.001), tumour thickness (HR = 1.4, P < 0.045) and ulceration (HR = 1.3, P < 0.008) as significant independent prognostic factors for MSS.
CONCLUSION
CONCLUSIONS
Although ER and LR patients are found to have different clinicopathologic features, the time of the first recurrence after diagnosis do not seem to have an effect on the survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-983Informations de copyright
© 2019 European Academy of Dermatology and Venereology.
Références
Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012; 30: 355-361.
Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
Röcken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 2010; 120: 1800-1803.
Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010; 23: 41-56.
Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
Faries MB, Steen S, Ye X, Sim M, Morton DL. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 2013; 217: 27-36.
Khanna AK, Laidler P, Hughes LE. Can late recurrence of melanoma be predicted at the time of primary treatment. Eur J Surg Oncol 1986; 12: 9-12.
Brauer JA, Wriston CC, Troxel AB et al. Characteristics associated with early and late melanoma metastases. Cancer 2010; 116: 415-423.
Levy E, Silverman MK, Vossaert KA et al. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res 1991; 1: 63-67.
Shaw HM, Beattie CW, McCarthy WH, Milton GW. Late relapse from cutaneous stage I malignant melanoma. Arch Surg 1985; 120: 1155-1159.
Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990; 212: 173-177.
Peters A, Lippold A, Hundeiker M. First melanoma metastases after 10 years and more of remission. Hautarzt 1997; 48: 311-317.
Hansel G, Schonlebe J, Haroske G, Wollina U. Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol 2010; 24: 833-836.
Schmid-Wendtner MH, Baumert J, Schmidt M et al. Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol 2000; 43: 605-609.
Leman JA, Mac Kie RM. Late (> 10 years) recurrence of melanoma: the Scottish experience. Br J Dermatol 2003; 148: 372-373.
Shen P, Guenther JM, Wanek LA, Morton DL. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol 2000; 7: 114-119.
Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997; 79: 2361-2370.
Tahery DP, Moy RL. Lack of predictive factors in late recurrence of stage I melanoma. Int J Dermatol 1992; 31: 629-631.
Callaway MP, Briggs JC. The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 1989; 42: 46-49.
Briele HA, Beattie CW, Ronan SG, Chaudhuri PK, Das Gupta TK. Late recurrence of cutaneous melanoma. Arch Surg 1983; 118: 800-803.
Yadav AS, Pandey PR, Butti R et al. The biology and therapeutic implications of tumor dormancy and reactivation. Front Oncol 2018; 8: 72.
Yeh AC, Ramaswamy S. Mechanisms of cancer cell dormancy- Another hallmark of cancer? Cancer Res 2015; 75: 5014-5022.
Gao XL, Zhang M, Tang YL, Liang XH. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis. Onco Targets Ther 2017; 10: 5219-5228.
Garrido F, Ruiz-Cabello F, Aptsiauri N. Rejection versus escape: the tumor MHC dilemma. Cancer Immunol Immunother 2017; 66: 259-271.
Carretero R, Wang E, Rodriguez AI et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012; 131: 387-395.
Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45-49.
Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178.
Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8: 400-414.
Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995; 75: 2492-2498.
Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
Richetta AG, Bottoni U, Paolino G et al. Thin melanoma and late recurrences: it is never too thin and never too late. Med Oncol 2014; 31: 909.
Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 2010; 74: 40-60.
Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2000; 89: 255-261.
Mohammadpour A, Derakhshan M, Darabi H, Hedayat P, Momeni M. Melanoma: Where we are and where we go. J Cell Physiol 2019; 234: 3307-3320.
Valpione S, Gremel G, Mundra P et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer 2018; 88: 1-9.
Navarrete-Dechent C, Cordova M, Liopyris K et al. Reflectance confocal microscopy and dermoscopy aid in evaluating repigmentation within or adjacent to lentigo maligna melanoma surgical scars. J Eur Acad Dermatol Venereol 2019. https://doi.org/10.1111/jdv.15819 [Epub ahead of print]